Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-14
2000-07-04
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514274, 544316, 544318, 544335, A01N 4354, A61K 31505, C07D23902
Patent
active
060839511
ABSTRACT:
Pyrimidine sulphonamide compounds of the following formula, ##STR1## wherein Q is a naphthyl or biphenyl group either unsubstituted or substituted with A.sup.1, and where A.sup.1, R.sup.1 and R.sup.2 are a variety of alkyl, aryl and cyclic moieties, as described in the specification hereof, which compounds are useful for the treatment of diseases or medical conditions such as hypertension, pulmonary hypertension, cardiac or cerebral circulatory disease and renal disease.
REFERENCES:
patent: 5270313 (1993-12-01), Burri et al.
patent: 5292740 (1994-03-01), Burri et al.
patent: 5302718 (1994-04-01), Agback et al.
patent: 5420129 (1995-05-01), Breu et al.
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5668137 (1997-09-01), Phillips et al.
R.D. Desai et al., "Studies in Sulphonamides: Part II. Preparation of N.sup.1 -Heterocyclic Substituted Sulphonamides from Alpha-naphthylamine and Evaluation of their Antibacterial Properties", Jour. Indian Chem. Soc., pp. 115-118, vol. 46, No. 2, 1969.
R.D. Desai et al., "Studies in Sulphonamides: Part IV. Some N.sup.6 -Heterocyclic Sulphonamides from 2-Naphthylamine as possible Antibacterial Agents", J. Indian Chem. Soc., pp. 411-414, vol. 46, No. 5, 1969.
P. Mamalis et al., "142. Some Heterocyclic N-Oxides", J. Chem. Soc., pp. 703-705, 1950.
Chemical Abstracts, vol. 84, No. 15, 1976, 84:100672y.
Chemical Abstracts, vol. 100, No. 15, 1984, 100:131420t.
Chemical Abstracts, vol. 106, No. 17, 1987, 106:133792p (corresponds to JP61257960).
Himel et al., "Fluorescent Analogs of Insecticides and Synergists. Synthesis and Reactions of Active-Site-Directed Fluorescent Probes", Journal Agr. Food Chem., vol. 19, No. 6, 1971, pp. 1175-1180.
Stein et al., The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ET.sub.A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesul fonamide, Journal of Medicinal Chemistry, Feb. 4, 1994, vol. 37, No. 3, pp. 329-331.
Identification of a New Class of ET.sub.A Selective Endothelin Antagonists by Pharmacophore Directed Screening, Biochemical and Biophysical Research Communications, May 30, 1994, vol. 201, No. 1, pp. 228-234. Chan et al.
Pharmacological Characterization of Bosentan, a New Potent Orally Active Nonpeptide Endothelin Receptor Antagonist, Journal Pharmacol. Exp. Therap., 1994, 270, 228-235, Clozel et al.
Pages copied from a book of abstracts provided in an International Business Communications Conference entitled "Endothelin Inhibitors--Advances in Therapeutic Application and Development", Philadelphia, PA, Jun. 9-10, 1994, 33 pages.
Mitchell Kenneth F.
Shah Mukund J.
Truong Tamthom N.
Zeneca Limited
LandOfFree
Aryl-substituted pyrimidine sulphonamide compounds as endothelin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl-substituted pyrimidine sulphonamide compounds as endothelin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl-substituted pyrimidine sulphonamide compounds as endothelin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486829